Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
Chaparian, R. R.; Harding, A. T.; Riebe, K.; Karlsson, A.; Sempowski, G. D.; Heaton, N. S.; Heaton, B. E.
Show abstract
Vaccines targeting SARS-CoV-2 have gained emergency FDA approval, however the breadth against emerging variants and the longevity of protection remains unknown. Post-immunization boosting may be required, perhaps on an annual basis if the virus becomes an endemic pathogen. Seasonal influenza virus vaccines are already developed every year, an undertaking made possible by a robust global vaccine production and distribution infrastructure. To create a seasonal combination vaccine targeting influenza viruses and SARS-CoV-2 that is also amenable to frequent reformulation, we have developed a recombinant influenza A virus (IAV) genetic platform that "reprograms" the virus to package an immunogenic domain of the SARS-CoV-2 spike (S) protein onto IAV particles. Vaccination with this combination vaccine elicits neutralizing antibodies and provides protection from lethal challenge with both pathogens. This technology may allow for leveraging of established influenza vaccine infrastructure to generate a cost-effective and scalable seasonal vaccine solution for both influenza and coronaviruses.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Optimizing the live attenuated influenza A vaccine backbone for high-risk patient groups 97%
- Nucleoside-modified mRNA-based influenza vaccines circumvent problems associated with H3N2 vaccine strain egg-adaptation 95%
- Differential recognition of computationally optimized H3 hemagglutinin influenza vaccine candidates by human antibodies 95%
Similar papers in this journal
- Antigenic and virological properties of an H3N2 variant that will likely dominate the 2021-2022 Northern Hemisphere influenza season 96%
- Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice 95%
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants 95%
Similar papers in this journal
- Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants. 96%
- Temperature impacts SARS-CoV-2 spike fusogenicity and evolution 95%
- A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine 95%
Similar papers in this journal
- Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses 96%
- Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19 disease in hamsters 96%
- Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.